Exchange: NASDAQ·Updated 07:55 PM EDT

HALO News

News
all
press releases
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
Zacks
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
Zacks
More News
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
Zacks
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European MarketsPR NewswireSAN DIEGO, Oct. 7, 2026SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme...
PR Newswire
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE Technology
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE Technology Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to...
PR Newswire
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Halozyme Announces Appointment of Jim Daly to its Board of Directors Halozyme Announces Appointment of Jim Daly to its Board of DirectorsPR NewswireSAN DIEGO, Sept. 30, 2026SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today...
PR Newswire
HALO May 2027 Options Begin Trading
Investors in Halozyme Therapeutics Inc (Symbol: HALO) saw new options become available today, for the May 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly avail...
Nasdaq News: Markets
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Zacks
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. FTNT, ABBNY, EAT and HALO are some such stocks.
Zacks
$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today
Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 15 years by 8.16% on an annualized basis producing an average annual return of 21.6%. Currently, Halozyme Therapeutics has a marketread more...
Benzinga
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Zacks

Advertisement|Remove ads.